Thiogenesis Therapeutics, Corp.
TTIPF
$0.44
$0.02897.03%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 850.10K | 822.20K | 780.00K | 741.40K | 829.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.23M | 3.55M | 3.67M | 3.85M | 2.71M |
| Operating Income | -3.23M | -3.55M | -3.67M | -3.85M | -2.71M |
| Income Before Tax | -3.01M | -3.31M | -3.48M | -3.75M | -2.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.01 | -3.31 | -3.48 | -3.75 | -2.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.01M | -3.31M | -3.48M | -3.75M | -2.55M |
| EBIT | -3.23M | -3.55M | -3.67M | -3.85M | -2.71M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.07 | -0.08 | -0.09 | -0.10 | -0.07 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.05 | -0.06 | -0.04 |
| EPS Diluted | -0.07 | -0.08 | -0.09 | -0.10 | -0.07 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.05 | -0.06 | -0.04 |
| Average Basic Shares Outstanding | 175.62M | 168.98M | 162.34M | 156.52M | 150.00M |
| Average Diluted Shares Outstanding | 175.62M | 168.98M | 162.34M | 156.52M | 150.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |